Trial Profile

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Darolutamide (Primary) ; Enzalutamide (Primary) ; Saruparib (Primary)
Indications Prostate cancer
Focus Adverse reactions
Acronyms PETRANHA
Sponsors AstraZeneca; AstraZeneca AB

15 Jun 2025 Planned End Date changed from 23 Jul 2031 to 10 Apr 2031.
15 Jun 2025 Planned primary completion date changed from 23 Jul 2031 to 10 Apr 2031.
10 Feb 2025 Planned End Date changed from 7 Nov 2030 to 23 Jul 2031.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com